A Study to Learn How Different Amounts of the Study Medicine Called PF-07940369 Are Tolerated and Act in the Body in Healthy Adults.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
30actual
Sites
1
Country
Belgium
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-15 | actual | When the study began enrolling |
| Primary completion | 2026-01-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-06 | actual | The whole study's end, after follow-up |
| First posted | 2026-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adults
Interventions
- Drug: PF-07940369
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment Emergent Adverse Events (AEs)
measured Baseline (Day 0) up to 35 days after last dose of study drug
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed